Platelets and their derived extracellular vesicles: The new generation of markers in non-small cell lung cancer management

Drug Discov Today. 2023 Jul;28(7):103616. doi: 10.1016/j.drudis.2023.103616. Epub 2023 May 18.

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. Circulating elements have gained significant interest in the diagnosis and prognosis of NSCLC patients. Among these, platelets (PLTs) and their derived extracellular vesicles (P-EVs) are emerging eligible biosources both in terms of number and carriers of genetic materials (RNA, proteins, and lipids). PLTs are mainly produced by the shedding of megakaryocytes and together with P-EVs, participate in a variety of pathological processes including thrombosis, tumor progression, and metastasis. Here, we performed an extensive literature review focusing on PLTs and P-EVs as potential diagnostic, prognostic, and predictive markers for NSCLC patient management.

Keywords: extracellular vesicles; non-small cell lung cancer; platelets; predictive marker; prognosis; tumor-educated platelets.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Platelets / metabolism
  • Blood Platelets / pathology
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / metabolism
  • Extracellular Vesicles* / metabolism
  • Humans
  • Lung Neoplasms* / metabolism
  • Prognosis